Reidenbach AG, Kemmerer ZA, Aydin D, et al. Conserved lipid and small molecule modulation of COQ8 reveals regulation of the ancient kinase-like UbiB family. Cell Chemical Biol. 2018;25(2):154-165.
Stefely JA, Reidenbach AG, Ulbrich A, et al. Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthesis. Mol Cell. 2015;57(2):83-94.
Andrew Reidenbach, Ph.D.
Andrew Reidenbach is a research scientist I in the Chemical Biology and Therapeutics Science (CBTS) Program at the Broad Institute of MIT and Harvard under the leadership of Stuart Schreiber. The goal of Reidenbach’s work is to discover small-molecule therapeutics for prion disease using a blend of high-throughput screening and focused biochemistry. He also co-leads efforts to identify small-molecule binders of genetically validated therapeutic targets using novel DNA-encoded libraries.
Prior to joining the Broad Institute in November 2017, Reidenbach earned his Ph.D. in biochemistry in the lab of Dave Pagliarini at the University of Wisconsin–Madison. He previously held a graduate internship with Amgen through the Chemistry-Biology Interface Training Program, and as an undergraduate participated in the National Science Foundation’s Research Experience for Undergraduates internship program at Vanderbilt University.
Reidenbach also holds a B.S. in biochemistry from the University of Wisconsin–Madison.
Contact Andrew Reidenbach via email at firstname.lastname@example.org.